Local and systemic Th17 immune response associated with advanced stage colon cancer

Journal of Surgical Research

Volumn 208, Issue , 2017, Pages 180-186

  Sharp, Stephen P ^a   Avram, Dorina ^b   Stain, Steven C ^a   Lee, Edward C ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; Colorectal cancer; IL 17; Inflammation; Th17

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 4; TUMOR NECROSIS FACTOR; CYTOKINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; COLON ADENOCARCINOMA; COLON CANCER; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LOCAL THERAPY; MALE; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; SYSTEMIC THERAPY; TH17 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; BLOOD; COLON TUMOR; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; TH17 CELLS;

EID: 84992735180     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2016.09.038     Document Type: Article

References (45)

1. 1 Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., Cancer statistics, 2009. CA Cancer J Clin 59 (2009), 225–249.
2. 2 Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
3. 3 Henry, C.J., Sedjo, R.L., Rozhok, A., et al. Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. BMC Cancer, 15, 2015, 123.
4. 4 Kang, M., Edmundson, P., Araujo-Perez, F., McCoy, A.N., Galanko, J., Keku, T.O., Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas. BMC Cancer, 13, 2013, 91.
5. 5 Olsen, H.W., Lawrence, W.A., Snook, C.W., Mutch, W.M., Risk factors and screening techniques in 500 patients with benign and malignant colon polyps. An urban community experience. Dis Colon Rectum 31 (1988), 216–221.
6. 6 Terzic, J., Grivennikov, S., Karin, E., Karin, M., Inflammation and colon cancer. Gastroenterology 138 (2010), 2101–2114.e5.
7. 7 Lee, W.S., Baek, J.H., You, D.H., Nam, M.J., Prognostic value of circulating cytokines for stage III colon cancer. J Surg Res 182 (2013), 49–54.
8. 8 Krzystek-Korpacka, M., Diakowska, D., Kapturkiewicz, B., Bebenek, M., Gamian, A., Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett 337 (2013), 107–114.
9. 9 Sobhani, I., Tap, J., Roudot-Thoraval, F., et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One, 6, 2011, e16393.
10. 10 Choi, J.W., Liu, H., Shin, D.H., et al. Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 13 (2013), 2361–2374.
11. 11 Liu, X., Jin, H., Zhang, G., et al. Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS One, 9, 2014, e106834.
12. 12 Iida, T., Iwahashi, M., Katsuda, M., et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 25 (2011), 1271–1277.
13. 13 Kato, T., Furumoto, H., Ogura, T., et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 282 (2001), 735–738.
14. 14 Chen, X., Wan, J., Liu, J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69 (2010), 348–354.
15. 15 Zhu, X., Mulcahy, L.A., Mohammed, R.A., et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res, 10, 2008, R95.
16. 16 Grivennikov, S.I., Wang, K., Mucida, D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491 (2012), 254–258.
17. 17 Wang, W., Li, X., Zheng, D., et al. Dynamic changes of peritoneal macrophages and subpopulations during ulcerative colitis to metastasis of colorectal carcinoma in a mouse model. Inflamm Res 62 (2013), 669–680.
18. 18 Qian, X., Chen, H., Wu, X., Hu, L., Huang, Q., Jin, Y., Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine, 2015 [Epub ahead of print].
19. 19 Miyauchi, E., Ogita, T., Miyamoto, J., et al. Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PLoS One, 8, 2013, e79735.
20. 20 Zhao, J., Bulek, K., Gulen, M.F., et al. Human colon tumors express a dominant-negative form of SIGIRR that promotes inflammation and colitis-associated colon cancer in mice. Gastroenterology 149 (2015), 1860–1871.e8.
21. 21 Galizia, G., Lieto, E., De Vita, F., et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 22 (2002), 473–482.
22. 22 Conticello, C., Pedini, F., Zeuner, A., et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 172 (2004), 5467–5477.
23. 23 Martin-Orozco, N., Dong, C., The IL-17/IL-23 axis of inflammation in cancer: friend or foe?. Curr Opin Investig Drugs 10 (2009), 543–549.
24. 24 Su, X., Ye, J., Hsueh, E.C., Zhang, Y., Hoft, D.F., Peng, G., Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184 (2010), 1630–1641.
25. 25 Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., Wang, R.F., Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 105 (2008), 15505–15510.
26. 26 Hu, J., Mao, Y., Li, M., Lu, Y., The profile of Th17 subset in glioma. Int Immunopharmacol 11 (2011), 1173–1179.
27. 27 Yamada, Y., Saito, H., Ikeguchi, M., Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J Surg Res 178 (2012), 685–691.
28. 28 Zhuang, Y., Peng, L.S., Zhao, Y.L., et al. CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology 143 (2012), 951–962.e8.
29. 29 Wang, K., Kim, M.K., Di Caro, G., et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41 (2014), 1052–1063.
30. 30 Song, X., He, X., Li, X., Qian, Y., The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol 13 (2016), 418–431.
31. 31 Shabgah, A.G., Fattahi, E., Shahneh, F.Z., Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol 31 (2014), 256–261.
32. 32 Gaffen, S.L., An overview of IL-17 function and signaling. Cytokine 43 (2008), 402–407.
33. 33 Ma, S., Cheng, Q., Cai, Y., et al. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 74 (2014), 1969–1982.
34. 34 Wang, L., Yi, T., Kortylewski, M., Pardoll, D.M., Zeng, D., Yu, H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206 (2009), 1457–1464.
35. 35 He, D., Li, H., Yusuf, N., et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184 (2010), 2281–2288.
36. 36 Nam, J.S., Terabe, M., Kang, M.J., et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68 (2008), 3915–3923.
37. 37 Numasaki, M., Watanabe, M., Suzuki, T., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175 (2005), 6177–6189.
38. 38 Bar-Eli, M., Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67 (1999), 12–18.
39. 39 Inozume, T., Hanada, K., Wang, Q.J., Yang, J.C., IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother 32 (2009), 109–117.
40. 40 Rosette, C., Roth, R.B., Oeth, P., et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26 (2005), 943–950.
41. 41 Roland, C.L., Harken, A.H., Sarr, M.G., Barnett, C.C. Jr., ICAM-1 expression determines malignant potential of cancer. Surgery 141 (2007), 705–707.
42. 42 Gu, K., Li, M.M., Shen, J., et al. Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-kappaB/ZEB1 signal pathway. Am J Cancer Res 5 (2015), 1169–1179.
43. 43 Wu, J., Du, J., Liu, L., et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One, 7, 2012, e50035.
44. 44 Liu, T., Peng, L., Yu, P., et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol 32 (2012), 1332–1339.
45. 45 Liu, J., Duan, Y., Cheng, X., et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407 (2011), 348–354.